Interferon-beta-induced changes in neuroimaging phenotypes of appetitive motivation and reactivity to emotional salience.
Adolescent
Adult
Affect
/ drug effects
Aged
Amygdala
/ diagnostic imaging
Anxiety
/ chemically induced
Depression
/ chemically induced
Facial Expression
Facial Recognition
/ drug effects
Female
Humans
Immunologic Factors
/ adverse effects
Interferon-beta
/ adverse effects
Magnetic Resonance Imaging
Male
Middle Aged
Motivation
/ drug effects
Reward
Ventral Striatum
/ diagnostic imaging
Young Adult
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
05
2019
revised:
11
09
2019
accepted:
27
09
2019
pubmed:
18
11
2019
medline:
26
9
2020
entrez:
18
11
2019
Statut:
ppublish
Résumé
Treatment with interferon (IFN) has been associated with depressive side effects. Previous neuroimaging studies have provided information about changes in brain activation patterns in patients under treatment with IFN-alpha, but the effect of other IFNs, or the role of the underlying disease, has yet to be clarified. In the present fMRI study, we looked at brain changes after 8 days of IFN-beta treatment in N = =17 healthy volunteers, thus avoiding the possible confound of the effects of underlying pathology in studies of IFN-treated patients with neurological or other medical disorders. We followed a symptom dimensional approach by simultaneously investigating two distinct symptom domains of depressiveness: negative affect (amygdala) and appetitive motivation (ventral striatum). In these early phases of IFN treatment we detected a selective change in neural substrates of appetitive motivation, consistent with the predominant symptomatic change recorded in psychopathology ratings. In contrast, the fMRI phenotype of negative affect, which is known to characterize disorders of affect involving anxiety and depressiveness as well as individual vulnerability to depression, was unchanged after treatment. These findings suggest that IFN may induce an affective syndrome through a mechanism involving down-regulation of appetitive motivation.
Identifiants
pubmed: 31734534
pii: S2213-1582(19)30370-5
doi: 10.1016/j.nicl.2019.102020
pmc: PMC6861625
pii:
doi:
Substances chimiques
Immunologic Factors
0
Interferon-beta
77238-31-4
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102020Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
Brain Behav Immun. 2014 Nov;42:222-31
pubmed: 25066466
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Biol Psychiatry. 2009 Feb 15;65(4):296-303
pubmed: 18801471
Biol Psychiatry. 2009 May 1;65(9):732-41
pubmed: 19150053
Mol Psychiatry. 2000 Nov;5(6):604-15
pubmed: 11126391
Arch Gen Psychiatry. 2004 Sep;61(9):877-89
pubmed: 15351766
Am J Psychiatry. 2009 Jun;166(6):702-10
pubmed: 19411368
Arch Gen Psychiatry. 2012 Oct;69(10):1044-53
pubmed: 23026954
Neuropsychopharmacology. 2017 Mar;42(4):801-810
pubmed: 27620550
Nat Rev Neurosci. 2008 Jan;9(1):46-56
pubmed: 18073775
Mult Scler Relat Disord. 2017 Oct;17:138-143
pubmed: 29055445
Auton Neurosci. 2000 Dec 20;85(1-3):127-32
pubmed: 11189019
J Clin Child Adolesc Psychol. 2018 Jan-Feb;47(1):142-156
pubmed: 28107039
Fortschr Neurol Psychiatr. 2003 Sep;71(9):469-76
pubmed: 12975732
Neuroimage. 2005 May 1;25(4):1112-23
pubmed: 15850729
Regul Pept. 2004 Jan 15;117(1):11-23
pubmed: 14687696
Immunity. 2016 Apr 19;44(4):901-12
pubmed: 27096319
Front Neuroendocrinol. 2012 Jan;33(1):116-25
pubmed: 22214786
Biol Psychiatry. 2002 May 1;51(9):693-707
pubmed: 11983183
Neuroimage. 2012 Feb 15;59(4):3222-6
pubmed: 22079507
Neuropsychopharmacology. 2013 Oct;38(11):2179-87
pubmed: 23657438
Biol Psychiatry. 2005 Dec 1;58(11):843-53
pubmed: 16043128
Cell Rep. 2014 Apr 24;7(2):436-447
pubmed: 24703850
Neurobiol Aging. 2008 Nov;29(11):1744-53
pubmed: 17543422
BMC Pharmacol Toxicol. 2015 Sep 22;16:25
pubmed: 26392348
Curr Pharm Des. 2005;11(8):973-84
pubmed: 15777248
Neurosci Biobehav Rev. 2011 Jan;35(3):537-55
pubmed: 20603146
Biol Mood Anxiety Disord. 2011 Nov 07;1(1):10
pubmed: 22738433
Brain Behav Immun. 2011 Feb;25(2):181-213
pubmed: 20970492
Anat Embryol (Berl). 2005 Dec;210(5-6):343-52
pubmed: 16208455
Hum Brain Mapp. 2007 May;28(5):373-82
pubmed: 16933299
Mult Scler. 2000 Apr;6(2):115-20
pubmed: 10773857
Neuroimage. 2009 Sep;47(3):891-6
pubmed: 19481155
PLoS One. 2018 Jun 4;13(6):e0198244
pubmed: 29864139
J Neuropsychiatry Clin Neurosci. 2011 Summer;23(3):261-76
pubmed: 21948887
J Cereb Blood Flow Metab. 1996 Jan;16(1):7-22
pubmed: 8530558
Sci Rep. 2020 Mar 9;10(1):4287
pubmed: 32152378
Neuroimage. 2006 Jun;31(2):790-5
pubmed: 16487726
Biol Psychiatry. 2012 Feb 15;71(4):286-93
pubmed: 22112927
Biol Psychiatry. 2010 Oct 15;68(8):748-54
pubmed: 20719303
Biol Psychiatry. 2008 Sep 15;64(6):505-12
pubmed: 18550030
Age (Dordr). 2012 Oct;34(5):1295-308
pubmed: 21853262
Biol Psychiatry. 2016 Feb 15;79(4):320-8
pubmed: 26169252
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Eur J Immunol. 2017 Nov;47(11):1918-1924
pubmed: 28742217
Biol Psychiatry. 2009 Sep 1;66(5):407-14
pubmed: 19423079
J Neurol. 2016 Jul;263(7):1418-26
pubmed: 27177997
Mol Psychiatry. 2016 May;21(5):642-9
pubmed: 26033244
Semin Clin Neuropsychiatry. 2002 Oct;7(4):234-42
pubmed: 12382206
Neurology. 2003 Dec 9;61(11):1524-7
pubmed: 14663036
Neuropsychopharmacology. 2012 May;37(6):1444-54
pubmed: 22353759
Neuroimage. 2006 Mar;30(1):151-9
pubmed: 16305825
Neuron. 2015 Feb 4;85(3):505-11
pubmed: 25654256
J Manag Care Spec Pharm. 2015 Aug;21(8):650-60
pubmed: 26233537
Depress Anxiety. 2013 Apr;30(4):297-306
pubmed: 23468190
Nature. 1996 Oct 31;383(6603):812-5
pubmed: 8893004
Neuropsychopharmacology. 2002 May;26(5):643-52
pubmed: 11927189
Neuropsychopharmacology. 2007 Nov;32(11):2384-92
pubmed: 17327884